You searched for "anti-VEGF"
Atrophy and anti-VEGF
1 August 2019
| Saruban Pasu
|
EYE - Vitreo-Retinal
The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
3 October 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Long term, Macular atrophy, neovascular age-related macular degeneration
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
Systemic pharmacology of intravitreal anti-VEGF
1 April 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Type 3 CNV and anti-VEGF
1 February 2019
| Saruban Pasu
|
EYE - Vitreo-Retinal
The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...
ROP anti-VEGF treatment review
The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP,...Endophthalmitis after intravitreal anti-VEGF injection
1 August 2019
| Sofia Rokerya
|
EYE - Vitreo-Retinal
The authors report the results of a retrospective multicentre study conducted at 17 retina referral centres to investigate the microbial spectrum of endophthalmitis after anti-VEGF injections. A total of 83 cases of culture-positive endophthalmitis (58.4%) were included. The most frequent...
Effect of anti-VEGF treatment on PED morphology
1 June 2015
| Jaya Myneni
|
EYE - Vitreo-Retinal
This retrospective study of 30 eyes assessed the effect of anti-VEGF on morphology of pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD). Thirty eyes of 28 patients with PED were compared to 30 eyes of 30 patients with...
Combined anti-VEGF and PDT for wet AMD
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
4 August 2021
| Su Young
|
EYE - Vitreo-Retinal
|
aflibercept, foveal avascular zone, neovascular age-related macular degeneration, ranibizumab, retinal vessel density
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
21st Century retinal laser treatment in the anti-VEGF era
1 June 2017
| John Awad, Prasad Rao
|
EYE - Vitreo-Retinal
In today’s world, macular laser treatment has a vital role in the treatment of diabetic macular oedema (DMO). DMO is one of the most common causes of visual impairment. Despite expensive intravitreal treatment courses of anti-VEGF, many will agree that...
Licence to save: a UK survey of anti-VEGF use for the eye
1 February 2017
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...